Filtered By:
Management: Hospitals
Procedure: Heart Valve Surgery

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 121 results found since Jan 2013.

Multiple Cerebral Infarctions in a Patient with Adenomyosis on Hormone Replacement Therapy: A Case Report
A 59-year-old woman was admitted to our hospital because of repeated episodes of bilateral hand weakness. She had a 10-year history of combined estrogen –progestin therapy for menopausal symptoms. Magnetic resonance imaging on admission showed multiple hyperintense lesions in bilateral cerebral and cerebellar cortices on diffusion-weighted imaging. Transesophageal echocardiography showed thrombus formation on the aortic valve and moderate aortic i nsufficiency. Laboratory test demonstrated elevated CA125 (334.8 U/mL) and D-dimer (7.0 µg/mL) levels.
Source: Journal of Stroke and Cerebrovascular Diseases - August 8, 2016 Category: Neurology Authors: Nanako Hijikata, Yuki Sakamoto, Chikako Nito, Noriko Matsumoto, Arata Abe, Akane Nogami, Takahiro Sato, Hiroyuki Hokama, Seiji Okubo, Kazumi Kimura Tags: Case Studies Source Type: research

Micro Interventional Devices wins FDA nod for Permaseal
Micro Interventional Devices said today it won FDA 510(k) clearance for its Permaseal transapical access and closure device. The Permaseal device is designed to allow surgeons to access and close the left-ventricle without having to suture the myocardium using the companies compliant soft-tissue PolyCor anchor technology. “The FDA market clearance of Permaseal is another tremendous achievement for MID. This exciting development comes fast on the heels of our recent European approval.  Sales in Europe are exceeding our early expectations.  With the US approval, coming earlier than expected, MID will be initiating ...
Source: Mass Device - July 29, 2016 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Micro Interventional Devices Source Type: news

Stroke Heroes 2016
The American Heart Association/American Stroke Association's Puget Sound Division, along with our sponsor Medtronic, congratulates the honorees for this year's Stroke Hero Awards. We had amazing stories sent to us. Thank you to all of you who submitted a nomination. Here are some of the inspiring individuals honored this year as a Stroke Hero. AMY MOORE, Stroke Survivor Amy is described as a truly an inspiring person who has never let her stroke stop her from accomplishing her goals. Her stroke was diagnosed at six months of age and left her legally blind. Amy learned Braille during her first two years of high school an...
Source: Healthy Living - The Huffington Post - July 12, 2016 Category: Consumer Health News Source Type: news

Taking Risk: Early Results From Teaching Hospitals’ Participation in the Center for Medicare and Medicaid Innovation Bundled Payments for Care Improvement Initiative
The authors describe observations from the 27 teaching hospitals constituting the Association of American Medical Colleges (AAMC) cohort in the Center for Medicare and Medicaid Innovation (CMMI) Bundled Payments for Care Improvement (BPCI) initiative. CMMI introduced BPCI in August 2011 and selected the first set of participants in January 2013. BPCI participants enter into Medicare payment arrangements for episodes of care for which they take financial risk. The first round of participants entered risk agreements on October 1, 2013 and January 1, 2014. In April 2014, CMMI selected additional participants who started takin...
Source: Academic Medicine - June 30, 2016 Category: Universities & Medical Training Tags: Articles Source Type: research

An approach to a patient with infective endocarditis.
Authors: Hitzeroth J, Beckett N, Ntuli P Abstract Although infective endocarditis (IE) is relatively uncommon, it remains an important clinical entity with a high in-hospital and 1-year mortality. It is most commonly caused by viridans streptococci. Staphylococcus aureus is responsible for a malignant course of IE and often requires early surgery to eradicate. Other rarer causes are various bacilli, including the HACEK (Haemophilus, Actinobacillus,Cardiobacterium, Eikenella and Kingella spp.) group of organisms and fungi. The clinical presentation varies. Patients may present with a nonspecific illness, valve dysfu...
Source: South African Medical Journal - June 17, 2016 Category: African Health Tags: S Afr Med J Source Type: research

MassDevice.com +5 | The top 5 medtech stories for June 15, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Biotronik wins CE Mark for Magmaris bioresorbable scaffold Biotronik said today it won CE Mark for its Magmaris magnesium bioresorbable scaffold designed to treat coronary artery disease. Data from the Biosolve-II trial of the ...
Source: Mass Device - June 15, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

A rare case of right ventricular myxoma causing recurrent stroke
We present a 62-year-old lady admitted in our hospital with two episodes of acute ischemic stroke about 2 weeks apart. She was evaluated for acute ischemic stroke and was thrombolysed for recent stroke in right MCA territory first time. On further evaluation, she was found to have a RVOT mass. A transthoracic and transesophageal echocardiogram revealed a PFO and a large, 5.1cm×2.3cm, ovoid, well circumscribed, echogenic mass in the right ventricle outflow tract attached by small pedicle to the ventricular side of anterior tricuspid leaflet, partly obstructing the right ventricular outflow tract and protruding through the ...
Source: Indian Heart Journal - May 20, 2016 Category: Cardiology Source Type: research

Edwards Lifesciences touts intermediate-risk data for Sapien devices | ACC 2016
Data from a large trial of the Sapien line of replacement heart valves made by Edwards Lifesciences (NYSE:EW) are slated to be used to back bids for expanded indications in intermediate-risk patients. Presented over the weekend at the American College of Cardiology’s annual meeting in Chicago, results from the Partner II trial involving the Sapien XT and Sapien 3 transcatheter aortic valve replacements compared the TAVR treatments with traditional open surgery in the intermediate-risk cohort (both of the Edwards valves are already approved in the U.S. for high-risk patients). Sapien XT non-inferior to surgery at 2...
Source: Mass Device - April 4, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Replacement Heart Valves American College of Cardiology Conference (ACC) Edwards Lifesciences Source Type: news

Rates of death and stroke equivalent for surgery and TAVR at two years
Intermediate-risk patients with severe aortic stenosis who receive minimally invasive transcatheter aortic valve replacement, known as TAVR, have similar rates of death and disabling strokes after two years compared with those undergoing standard open heart surgical replacement, according to a new study. Patients receiving TAVR also experienced shorter hospital stays and lower incidence of some major complications compared with those undergoing surgery.
Source: ScienceDaily Headlines - April 3, 2016 Category: Science Source Type: news

At UCLA, it's medicine 2.0
Tucked deep in the basement of UCLA’s Center for the Health Sciences is a room that looks more like an inventor’s fantasy workshop than the medical research facility it is. Tables are piled high with tools, electronics, prototype equipment parts and a few stray robotic arms. Posters on the wall describe pending projects in dense technical language with accompanying photos of futuristic devices. This hidden space is where scientists are working at the very forefront of technological advances in medicine. Its assemblage of smarts, parts and computers is contributing to an emerging era of personalized, tech-enabled health...
Source: UCLA Newsroom: Health Sciences - December 16, 2015 Category: Universities & Medical Training Source Type: news

Prophylactic Subclavian Artery Intraaortic Balloon Counter-Pulsation is Safe in High-Risk Cardiac Surgery Patients
The objective of this study was to determine the safety of prophylactic subclavian artery intraaortic balloon pumps (SCA-IABP) in high-risk cardiac surgery patients as a bridge to recovery (BTR). From November 2011 to January 2013, 11 consecutive patients at three institutions underwent prophylactic insertion of a SCA-IABP as a BTR. All patients (n = 11) had preoperative ejection fractions of 30% or less. Patients concurrently underwent one or a combination of the following procedures: coronary artery bypass grafting, mitral valve surgery, aortic valve replacement, left ventricular aneurysm resection, and ventricular/atria...
Source: ASAIO Journal - September 1, 2015 Category: Medical Equipment Tags: Case Series Source Type: research

From FRANCE 2 to FRANCE TAVI: Are indications, technique and results of transcatheter aortic valve replacement the same?
Abstract Transcatheter aortic valve implantation (TAVI) is indicated in patients with severe symptomatic aortic stenosis who are not suitable for surgery or should be considered when there is a high surgical risk as assessed by a heart team. There is a decrease in mean logistic EuroSCORE since January 2010, which translates a gradual evolution in patients' selection. Expertise of geriatricians to further assess frailty is a key step in the risk stratification process of this elderly population (mean age: 83.4±7.3 years). Femoral access is used in 80% of cases with a procedural success rate higher than 95%. In-hos...
Source: Presse Medicale - July 21, 2015 Category: Journals (General) Authors: Auffret V, Bedossa M, Boulmier D, Verhoye JP, Ruggieri VG, Koning R, Laskar M, Van Belle É, Leprince P, Collet JP, Iung B, Lefèvre T, Eltchaninoff H, Gilard M, Le Breton H Tags: Presse Med Source Type: research

In-hospital mortality and stroke after surgical aortic valve replacement: A nationwide perspective
Stroke is a widely recognized complication after aortic valve replacement (AVR), especially among elderly patients. The literature contains substantial variability in reports of the actual incidence of stroke after AVR among high-risk patients. Our objective was to define risk of stroke in patients undergoing surgical AVR, using a large national database.
Source: The Journal of Thoracic and Cardiovascular Surgery - June 4, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Shikhar Agarwal, Aatish Garg, Akhil Parashar, Lars G. Svensson, E. Murat Tuzcu, Jose L. Navia, Stephanie Mick, Samir R. Kapadia Tags: Acquired cardiovascular disease Source Type: research

In-hospital Mortality and Stroke Following Surgical Aortic Valve Replacement: A Nationwide Perspective
Stroke is a widely recognized complication following aortic valve replacement (AVR), especially among elderly patients. Significant heterogeneity exists in the current literature around the actual incidence of stroke following AVR among high-risk patients. Our objective was to define risk of stroke in patients undergoing surgical AVR from a large national database.
Source: The Journal of Thoracic and Cardiovascular Surgery - June 4, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Shikhar Agarwal, Aatish Garg, Akhil Parashar, Lars G. Svensson, E. Murat Tuzcu, Jose Navia, Stephanie Mick, Samir R. Kapadia Source Type: research

Cardiovascular highlights from non-cardiology journals
Long-Term Outcomes of Transcatheter Aortic Valve Replacement The Placement of Aortic Transcatheter Valves (PARTNER) trial demonstrated that transcatheter aortic valve replacement (TAVR) for high-risk patients with aortic stenosis resulted in similar outcomes at 1, 2 and 3 years compared with surgical aortic valve replacement (SAVR). The present study reports the 5-year outcomes of this trial. The study enrolled 699 patients who were randomized to SAVR or TAVR (via a transfemoral or transapical approach). Overall, mean age was 84.1 years, 94% were NYHA Class 3 or 4, and the mean Society of Thoracic Surgeons Predicted Risk o...
Source: Heart - May 25, 2015 Category: Cardiology Authors: Bradley, S. M. Tags: Journal scan Source Type: research